Neuroleptic exposure in bipolar outpatients in a research setting

Kirk D. Denicoff, Ann B. Sollinger, Mark A Frye, S. Omar Ali, Earlian E. Smith-Jackson, Gabriele S. Leverich, Robert M. Post

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The study purpose was to determine the extent of neuroleptic exposure in bipolar outpatients maintained on mood-stabilizing medications and any clinical correlates associated with this exposure. Data on medication and severity of illness were gathered from the records (prospective and retrospective) of 70 bipolar patients involved in outpatient research studies at the National Institute of Mental Health (NIMH). The percentage of patients requiring neuroleptic treatment, percentage of time on neuroleptics during the period of observation, total dose of neuroleptics in chlorpromazine (CPZ) equivalency, and number of neuroleptic trials were among the variables calculated. Regression analyses and analyses of variance (ANOVAs) were performed to assess the relationships between neuroleptic exposure and clinical course. Forty-five patients (64.3%) had a neuroleptic trial during the prospective study. Subjects exposed to neuroleptics spent, on average, 15.4% (median, 6.0%) of the time in study on neuroleptic treatment, and were administered, on average, a total of 11,770.5 mg (median, 1,621.9 mg) of neuroleptics (in CPZ equivalency) per year in the prospective study. As expected, bipolar I compared with bipolar II patients had significantly higher neuroleptic exposure by a number of measures. The number of hospitalizations for mania prior to study entry was associated with greater prospective neuroleptic use during the study. Despite maintenance treatment with one or more mood-stabilizing agents, we found a relatively high need for adjunctive neuroleptic medication even in this sample of high-functioning bipolar outpatients. These results highlight the need for the study of alternatives, as well as more effective primary mood-stabilizing agents. This is a US government work. There are no restrictions on its use.

Original languageEnglish (US)
Pages (from-to)248-252
Number of pages5
JournalComprehensive Psychiatry
Volume41
Issue number4
DOIs
StatePublished - Jul 2000
Externally publishedYes

Fingerprint

Antipsychotic Agents
Outpatients
Research
Excipients
Chlorpromazine
Prospective Studies
National Institute of Mental Health (U.S.)
Bipolar Disorder
Analysis of Variance
Hospitalization
Therapeutics
Regression Analysis
Observation

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Denicoff, K. D., Sollinger, A. B., Frye, M. A., Omar Ali, S., Smith-Jackson, E. E., Leverich, G. S., & Post, R. M. (2000). Neuroleptic exposure in bipolar outpatients in a research setting. Comprehensive Psychiatry, 41(4), 248-252. https://doi.org/10.1053/comp.2000.7430

Neuroleptic exposure in bipolar outpatients in a research setting. / Denicoff, Kirk D.; Sollinger, Ann B.; Frye, Mark A; Omar Ali, S.; Smith-Jackson, Earlian E.; Leverich, Gabriele S.; Post, Robert M.

In: Comprehensive Psychiatry, Vol. 41, No. 4, 07.2000, p. 248-252.

Research output: Contribution to journalArticle

Denicoff, KD, Sollinger, AB, Frye, MA, Omar Ali, S, Smith-Jackson, EE, Leverich, GS & Post, RM 2000, 'Neuroleptic exposure in bipolar outpatients in a research setting', Comprehensive Psychiatry, vol. 41, no. 4, pp. 248-252. https://doi.org/10.1053/comp.2000.7430
Denicoff KD, Sollinger AB, Frye MA, Omar Ali S, Smith-Jackson EE, Leverich GS et al. Neuroleptic exposure in bipolar outpatients in a research setting. Comprehensive Psychiatry. 2000 Jul;41(4):248-252. https://doi.org/10.1053/comp.2000.7430
Denicoff, Kirk D. ; Sollinger, Ann B. ; Frye, Mark A ; Omar Ali, S. ; Smith-Jackson, Earlian E. ; Leverich, Gabriele S. ; Post, Robert M. / Neuroleptic exposure in bipolar outpatients in a research setting. In: Comprehensive Psychiatry. 2000 ; Vol. 41, No. 4. pp. 248-252.
@article{f8c13036d16c46b8af1f8889d2a97565,
title = "Neuroleptic exposure in bipolar outpatients in a research setting",
abstract = "The study purpose was to determine the extent of neuroleptic exposure in bipolar outpatients maintained on mood-stabilizing medications and any clinical correlates associated with this exposure. Data on medication and severity of illness were gathered from the records (prospective and retrospective) of 70 bipolar patients involved in outpatient research studies at the National Institute of Mental Health (NIMH). The percentage of patients requiring neuroleptic treatment, percentage of time on neuroleptics during the period of observation, total dose of neuroleptics in chlorpromazine (CPZ) equivalency, and number of neuroleptic trials were among the variables calculated. Regression analyses and analyses of variance (ANOVAs) were performed to assess the relationships between neuroleptic exposure and clinical course. Forty-five patients (64.3{\%}) had a neuroleptic trial during the prospective study. Subjects exposed to neuroleptics spent, on average, 15.4{\%} (median, 6.0{\%}) of the time in study on neuroleptic treatment, and were administered, on average, a total of 11,770.5 mg (median, 1,621.9 mg) of neuroleptics (in CPZ equivalency) per year in the prospective study. As expected, bipolar I compared with bipolar II patients had significantly higher neuroleptic exposure by a number of measures. The number of hospitalizations for mania prior to study entry was associated with greater prospective neuroleptic use during the study. Despite maintenance treatment with one or more mood-stabilizing agents, we found a relatively high need for adjunctive neuroleptic medication even in this sample of high-functioning bipolar outpatients. These results highlight the need for the study of alternatives, as well as more effective primary mood-stabilizing agents. This is a US government work. There are no restrictions on its use.",
author = "Denicoff, {Kirk D.} and Sollinger, {Ann B.} and Frye, {Mark A} and {Omar Ali}, S. and Smith-Jackson, {Earlian E.} and Leverich, {Gabriele S.} and Post, {Robert M.}",
year = "2000",
month = "7",
doi = "10.1053/comp.2000.7430",
language = "English (US)",
volume = "41",
pages = "248--252",
journal = "Comprehensive Psychiatry",
issn = "0010-440X",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Neuroleptic exposure in bipolar outpatients in a research setting

AU - Denicoff, Kirk D.

AU - Sollinger, Ann B.

AU - Frye, Mark A

AU - Omar Ali, S.

AU - Smith-Jackson, Earlian E.

AU - Leverich, Gabriele S.

AU - Post, Robert M.

PY - 2000/7

Y1 - 2000/7

N2 - The study purpose was to determine the extent of neuroleptic exposure in bipolar outpatients maintained on mood-stabilizing medications and any clinical correlates associated with this exposure. Data on medication and severity of illness were gathered from the records (prospective and retrospective) of 70 bipolar patients involved in outpatient research studies at the National Institute of Mental Health (NIMH). The percentage of patients requiring neuroleptic treatment, percentage of time on neuroleptics during the period of observation, total dose of neuroleptics in chlorpromazine (CPZ) equivalency, and number of neuroleptic trials were among the variables calculated. Regression analyses and analyses of variance (ANOVAs) were performed to assess the relationships between neuroleptic exposure and clinical course. Forty-five patients (64.3%) had a neuroleptic trial during the prospective study. Subjects exposed to neuroleptics spent, on average, 15.4% (median, 6.0%) of the time in study on neuroleptic treatment, and were administered, on average, a total of 11,770.5 mg (median, 1,621.9 mg) of neuroleptics (in CPZ equivalency) per year in the prospective study. As expected, bipolar I compared with bipolar II patients had significantly higher neuroleptic exposure by a number of measures. The number of hospitalizations for mania prior to study entry was associated with greater prospective neuroleptic use during the study. Despite maintenance treatment with one or more mood-stabilizing agents, we found a relatively high need for adjunctive neuroleptic medication even in this sample of high-functioning bipolar outpatients. These results highlight the need for the study of alternatives, as well as more effective primary mood-stabilizing agents. This is a US government work. There are no restrictions on its use.

AB - The study purpose was to determine the extent of neuroleptic exposure in bipolar outpatients maintained on mood-stabilizing medications and any clinical correlates associated with this exposure. Data on medication and severity of illness were gathered from the records (prospective and retrospective) of 70 bipolar patients involved in outpatient research studies at the National Institute of Mental Health (NIMH). The percentage of patients requiring neuroleptic treatment, percentage of time on neuroleptics during the period of observation, total dose of neuroleptics in chlorpromazine (CPZ) equivalency, and number of neuroleptic trials were among the variables calculated. Regression analyses and analyses of variance (ANOVAs) were performed to assess the relationships between neuroleptic exposure and clinical course. Forty-five patients (64.3%) had a neuroleptic trial during the prospective study. Subjects exposed to neuroleptics spent, on average, 15.4% (median, 6.0%) of the time in study on neuroleptic treatment, and were administered, on average, a total of 11,770.5 mg (median, 1,621.9 mg) of neuroleptics (in CPZ equivalency) per year in the prospective study. As expected, bipolar I compared with bipolar II patients had significantly higher neuroleptic exposure by a number of measures. The number of hospitalizations for mania prior to study entry was associated with greater prospective neuroleptic use during the study. Despite maintenance treatment with one or more mood-stabilizing agents, we found a relatively high need for adjunctive neuroleptic medication even in this sample of high-functioning bipolar outpatients. These results highlight the need for the study of alternatives, as well as more effective primary mood-stabilizing agents. This is a US government work. There are no restrictions on its use.

UR - http://www.scopus.com/inward/record.url?scp=0034234541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034234541&partnerID=8YFLogxK

U2 - 10.1053/comp.2000.7430

DO - 10.1053/comp.2000.7430

M3 - Article

VL - 41

SP - 248

EP - 252

JO - Comprehensive Psychiatry

JF - Comprehensive Psychiatry

SN - 0010-440X

IS - 4

ER -